Share
Journal Information
Issue
Vol. 41. Issue 9.Pages 729-812 (September 2022)
Original articles
The predictive value of epicardial fat volume for clinical severity of COVID-19
Mehmet Akif Erdöl, Fatma Civelek Eser, Abdullah Nabi Aslan, Mehmet Erdoğan, Adalet Altunsoy Aypak, Muhammed Said Beşler, Ayşe Kaya Kalem, Ahmet Göktuğ Ertem, Hatice Rahmet Güner
Rev Port Cardiol. 2022;41:729-37
Open access
Original Articles
Editorial comment
Epicardial fat as a predictor of COVID-19 disease severity: Just a surrogate for obesity or a true independent predictor?
Christopher Strong
Rev Port Cardiol. 2022;41:739-40
Open access
Chronic thromboembolic pulmonary hypertension: A 10-year analysis from a Portuguese referral center
Gonçalo Samouco, Marta Fonseca, Joana Batista Correia, Cátia Santos-Ferreira, Patrícia Marques-Alves, Rui Baptista, Graça Castro, Lino Gonçalves
Rev Port Cardiol. 2022;41:741-8
Open access
Original Articles
Editorial comment
Therapeutic options for thromboembolic pulmonary hypertension: An overview of the situation in Portugal
Filipa Ferreira
Rev Port Cardiol. 2022;41:749-50
Open access
The prognostic value of the cardiorespiratory optimal point during submaximal exercise testing in heart failure
João Ferreira Reis, António Gonçalves, Pedro Brás, Rita Moreira, Tiago Pereira-da-Silva, Ana Teresa Timóteo, Rui Soares, Rui Cruz Ferreira
Rev Port Cardiol. 2022;41:751-8
Open access
Original Articles
Editorial comment
Cardiopulmonary exercise testing for heart failure prognosis: What to prioritize – maximal aerobic power or submaximal efficiency parameters?
Helena Santa-Clara
Rev Port Cardiol. 2022;41:759-60
Open access
Index of microcirculatory resistance in the assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy
Sílvia Aguiar Rosa, Miguel Mota Carmo, Luís Rocha Lopes, Eunice Oliveira, Boban Thomas, Luis Baquero, Rui Cruz Ferreira, António Fiarresga
Rev Port Cardiol. 2022;41:761-7
Open access
Original Articles
Editorial comment
Invasive versus non-invasive coronary microvascular assessment in hypertrophic myocardiopathy – Are we measuring the same thing?
Nuno Bettencourt
Rev Port Cardiol. 2022;41:769-70
Open access
Echocardiographic assessment of atrial function in patients with hypertrophic cardiomyopathy with and without paroxysmal atrial fibrillation
Kamilla Leite Morbeck Teixeira, Edileide de Barros Correia, Cíntia Galhardo Tressino, Marcela Momesso Peçanha, Walter Antonio Melchior, Rodrigo Bellio de Mattos Barretto, Bruna Gomes de Medeiros, David Le Bihan
Rev Port Cardiol. 2022;41:771-9
Open access
Original Articles
Editorial comment
Should atrial function be routinely assessed in hypertrophic cardiomyopathy?
Luís R. Lopes
Rev Port Cardiol. 2022;41:781-2
Open access
State of the art
Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?
Sérgio Barra, João Primo, Helena Gonçalves, Serge Boveda, Rui Providência, Andrew Grace
Rev Port Cardiol. 2022;41:783-9
Open access
Original articles
Original Articles
Editorial comment
Contributions to the improvement of healthcare management for cardiovascular patients in Portugal
Adalberto Campos Fernandes, Ana Abreu, Fausto Pinto, Hélder Mota-Filipe, Maria do Céu Machado, Manuel Carrageta
Rev Port Cardiol. 2022;41:791-3
Open access
Case report
Hemangioma of the mitral valve: Following the murmur
Manuel Toscano, Ana Rafaela Alves, Carla Matias, Madalena Carvalho, Marta Marques
Rev Port Cardiol. 2022;41:795-9
Open access
Original articles
Original Articles
Editorial comment
Image in cardiology
Troubled adolescence
Rita Caldeira da Rocha, Renato Fernandes, Bruno Piçarra, David Neves, Manuel Trinca
Rev Port Cardiol. 2022;41:803-4
Open access
Research letter
Paradoxical effect of lipid lowering therapy in homozygous familial hypercholesterolemia: Atherosclerotic plaque calcifications and increased cardiovascular events
Tiziana Sampietro, Francesco Sbrana, Federico Bigazzi, Beatrice Dal Pino
Rev Port Cardiol. 2022;41:805-7
Open access
Letters to the editors
Letter to the editor regarding the article: “Inflammation and Ischemic heart disease: the next therapeutic target?”
Luís Bronze
Rev Port Cardiol. 2022;41:809-10
Open access
Reply to Letter to the editor regarding the article: “Inflammation and ischemic heart disease: The next therapeutic target?”
Eduardo M. Vilela, Ricardo Fontes-Carvalho
Rev Port Cardiol. 2022;41:811-2
Open access
Publish in
Revista Portuguesa de Cardiologia
Revista Portuguesa de Cardiologia (English edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.
www.publicationethics.org.